ObesityNCT02389556
Serum ANGPTL3, ANGPTL8 and Glypican 4 Concentrations in Relation to the Development of Obesity in Korean Children
An observational study of Obesity, run by Korea University at 1 site in South Korea.
Trial summary
ANGPTL3 and ANGPTL8 are emerging molecules involving lipid metabolism. In previous in vivo study using mice, ANGPTL8 regulated the activation of ANGPTL3 which was known to inhibit lipoprotein lipase activity and stimulate lipolysis of adipose tissue. Read more about this study
- Who is it for?
- Ages 9 to 12 yearsHealthy volunteers can take part
- Conditions the study is for
- Obesity
- How many people
- 457 participants
- Where
- 1 siteSouth Korea
- Study dates
- Jan 2006to Dec 2011
- How long will I take part?
- 3 Years
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 9 to 12 years
- All sexes
- Healthy volunteers accepted
- Child
Study population: Participants in this study were selected from the Korean Metabolic disorders \& Obesity Study in Elementary School children (KMOSES).
Who may be able to join
- Participants who were reexamined for the 3 year follow-up assessment
Who cannot join
- Participants who were not being available for the 3 year follow up assessment
Trial locations and contacts
1 site in 1 country.
South Korea1 site
Department of Internal Medicine, Korea University College of Medicine
Seoul, VD, 152-703
About this study
Official title: Serum ANGPTL3, ANGPTL8 and Glypican 4 Concentrations in Relation to the Development of Obesity in Korean Children: a Three Year Prospective Cohort Study
ANGPTL3 and ANGPTL8 are emerging molecules involving lipid metabolism. In previous in vivo study using mice, ANGPTL8 regulated the activation of ANGPTL3 which was known to inhibit lipoprotein lipase activity and stimulate lipolysis of adipose tissue. Besides, glypican 4 was identified as a novel adipokine modulating adipocyte differentiation. Thus, the investigators postulated that different serum concentrations of ANGPTL3, ANGPTL8 and glypican 4 might affect progression of obesity in children. The investigators measure these molecules in Korean children, and investigate the association between these molecules and development of obesity.
Read the detailed description
Participants in this study were selected from the Korean Metabolic disorders \& Obesity Study in Elementary School children (KMOSES), the main aim of which was to comprehensively assess obesity-related metabolic risk factors and to evaluate clinical outcomes in Korean children prospectively. Korean children who were participated in a school-based health examination, were reexamined for the 3-year follow-up assessment.
- Conditions
- Obesity
- Medical subject headings
- Obesity
What is being measured
The primary outcome is the main question the study is designed to answer.
The changes of body mass index according to serum level of ANGPTL3, ANGPTL8 and glypican 4
Measured: Baseline and 3 years
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted17 Mar 2015 (estimated)
- Study startJan 2006
- Primary completionDec 2011
- Study completionDec 2011
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for ObesityStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 457 participants (actual)
- Target duration
- 3 Years
Sponsor and investigators
- Lead sponsor
- Korea University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Kyung Mook Choi, Korea University
- Investigators
- Kyung Mook Choi, MD, Principal investigator, Department of Internal Medicine, Korea University College of Medicine
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT02389556
- Sponsor's protocol ID
- KMOSES
- Status last verified
- Feb 2016
- First submitted
- 10 Mar 2015
- Last updated
- 1 Mar 2016
- Results posted
- No
- Data monitoring committee
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 1 Mar 2016. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Serum ANGPTL3, ANGPTL8 and Glypican 4 Concentrations in Relation to the Development of Obesity in Korean Children: a Three Year Prospective Cohort Study
- ClinicalTrials.gov ID
- NCT02389556
- Acronym / sponsor ID
- KMOSES
- Conditions
- Obesity
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 457 participants (actual)
- Lead sponsor
- Korea UniversityUniversity, hospital or other
- Study start
- Jan 2006
- Primary completion
- Dec 2011 (actual)
- Study completion
- Dec 2011 (actual)
- First posted
- 17 Mar 2015 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
ANGPTL3 and ANGPTL8 are emerging molecules involving lipid metabolism. In previous in vivo study using mice, ANGPTL8 regulated the activation of ANGPTL3 which was known to inhibit lipoprotein lipase activity and stimulate lipolysis of adipose tissue. Besides, glypican 4 was identified as a novel adipokine modulating adipocyte differentiation. Thus, the investigators postulated that different serum concentrations of ANGPTL3, ANGPTL8 and glypican 4 might affect progression of obesity in children. The investigators measure these molecules in Korean children, and investigate the association between these molecules and development of obesity.
Detailed description
Participants in this study were selected from the Korean Metabolic disorders \& Obesity Study in Elementary School children (KMOSES), the main aim of which was to comprehensively assess obesity-related metabolic risk factors and to evaluate clinical outcomes in Korean children prospectively. Korean children who were participated in a school-based health examination, were reexamined for the 3-year follow-up assessment.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Target follow-up
- 3 Years
Who may qualify
- Ages
- 9 to 12 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Child
- Study population
- Participants in this study were selected from the Korean Metabolic disorders \& Obesity Study in Elementary School children (KMOSES).
Key inclusion criteria (1 listed)
- Participants who were reexamined for the 3 year follow-up assessment
Key exclusion criteria (1 listed)
- Participants who were not being available for the 3 year follow up assessment
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
The changes of body mass index according to serum level of ANGPTL3, ANGPTL8 and glypican 4
Time frame: Baseline and 3 years
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 1 Mar 2016.
- Individual participant dataSharing planned: No
Related trials for Obesity
RecruitingObservational study
Endoscopic Sleeve Gastroplasty (ESG) Prospective Trial for Obesity (EGO-Trial)
Obesity
Active, not recruitingPhase 4
Effects of Sequential Therapy With Mexidol® (Intravenous) and Mexidol® FORTE 250 (Oral) on Functional Brain Activity Assessed by Functional Magnetic Resonance Imaging and Biochemical Parameters in Patients With Chronic Cerebral Ischemia: A Comparison of Patients With and Without Metabolic Disorders
Metabolic Abnormalities, Obesity & Overweight
Recruiting
Exercise Training and Vitamin D Metabolism
Obesity & Overweight, Vitamin D
Recruiting
Metabolic Health, Bones and Nuts During Weight Loss in Adults
Weight Loss, Bone Density
Active, not recruiting
Effect of Probiotics on Insulin Sensitivity in Overweight and Obese Pregnancy
Obesity & Overweight, Gestational Diabetes Mellitus (GDM)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Kyung Mook Choi, MD principal investigator
Department of Internal Medicine, Korea University College of Medicine
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Obesity, run by Korea University at 1 site in South Korea.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 1 Mar 2016. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in South Korea. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
The changes of body mass index according to serum level of ANGPTL3, ANGPTL8 and glypican 4 (time frame: Baseline and 3 years). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 1 Mar 2016.